You don't need a lot of supplies or pill tracking or anything else
GLP-1 agonists Market Access and Reimbursement This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM
The most commonly reported adverse reactions in clinical trials include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and constipation, which occur in a substantial proportion of patients
Based on current evidence, GLP-1 microdosing is a complementary approach, not a replacement for standard immunotherapy
If avoiding pregnancy is essential (or if vomiting/diarrhea is common), discussing a non-oral, long-acting method especially one that can also help endometriosis symptomsmay be the simplest risk-reduction move
[25] [26] mhra.gov.uk